The ClockBinaries ticking down — call itview all →
PCVX
VAX-31
Ph3 Oct'26
--
no votes yet
AGIO
mitapivat
PDUFA November 1, 2026
--
no votes yet
CYTK
aficamten
PDUFA November 14, 2026
--
no votes yet
SMMT
ivonescimab (HARMONi BLA)
Ph3 November 14, 2026
--
no votes yet
CAPR
deramiocel
PDUFA November 22, 2026
--
no votes yet
SNY
venglustat
Ph3 November 25, 2026
--
no votes yet
BBIO
BBP-418
PDUFA November 27, 2026
--
no votes yet
COGT
bezuclastinib
PDUFA November 30, 2026
--
no votes yet

Public-market balance sheet screen

listed life-science balance sheets. One screen.

Search the screening universe by ticker or company, then sort the capital structure that matters: cash, debt, enterprise value and diluted share count.

Subscribe on Substack Snapshot: Oct 30, 2026
Prices update daily
Full rebuild weekly
listed companies
Cash figures reported
Share counts reported
Live Wire Full wire →
  • Connecting to the wire…

Readout Radar

150 trial readouts expected in the next 90 days

Full catalyst calendar
  • Now - Nov 4, 2026 ACRV ACR-2316 Phase 1
  • Now - Nov 11, 2026 BMRN BMN 349 Phase 1
  • Now - Nov 17, 2026 CLRB CLR 131 Phase 1
  • Now - Nov 22, 2026 GENB GB-7624 Phase 1
  • Now - Nov 22, 2026 MSLE SAT-3247 Phase 2
  • Now - Nov 23, 2026 NRIX NX-1607 Phase 1
  • Now - Nov 24, 2026 ALKS Olanzapine Phase 3
  • Now - Nov 24, 2026 ARDX Tenapanor 50 MG Phase 3

Readout Calendar

ClinicalTrials.gov primary-completion estimates plus management-guided timings. Registry windows are directional; guided timings are company-stated.

Primary completion + 6 to 12 weeks

Next 7 days

  • ARVN ARV-102 Oct 1–31, 2026
  • BHVN BHV-1530 Oct 1–31, 2026
  • BNTC BB-301 Oct 1–31, 2026
  • CLNN CNM-Au8 Oct 1–31, 2026
  • GANX rexaceract (GT-02287) Oct 1–31, 2026
  • IDYA darovasertib Oct 1–31, 2026
  • IMTX IMA203CD8 Oct 1–31, 2026
  • MGNX MGC026 Oct 1–31, 2026
No companies match.Adjust the screener or clear all filters.

MethodologyPrices from market data; cash, debt and shares from latest SEC filings. Debt is set to zero only where filings disclose no debt; EV and net cash stay blank when an input is unavailable. “Shares Out” uses basic shares outstanding where available, otherwise the stated basis. True FDSO adds disclosed options, RSUs, warrants and convertible securities to basic shares; each FDSO cell carries its coverage basis. “Mkt Cap × Cash” is market cap divided by cash; it is blank when cash is zero, negative, or unavailable. “FDMC × Net Cash” is FD market cap divided by net cash; it is blank when net cash is zero or an input is unavailable.

Material Events